By BullScreen Editorial Team 
Indian drugmakers have moved swiftly to capture a fast-growing obesity and diabetes market after the patent expiry of semaglutide, a blockbuster therapy originally developed by Novo Nordisk.
At least eight domestic pharmaceutical companies, including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Torrent Pharmaceuticals, Natco Pharma and Alkem Laboratories, have launched generic versions of the drug following the end of patent protection in India.
Semaglutide, sold globally under brands such as Ozempic and Wegovy, belongs to a class of GLP-1 receptor agonists that help regulate blood sugar, slow digestion and suppress appetite. The drug has gained significant traction worldwide for both diabetes management and weight loss.
Indian versions are being introduced at sharply lower prices, ranging from ₹1,300 to ₹4,500 per month, compared with ₹8,800–₹16,400 for the original formulations. Alkem said its product is priced as low as ₹1,800 per month, following approval from the Drug Controller General of India after local Phase 3 trials.
Most companies are offering both injectable and oral formats, targeting a broad patient base. However, firms emphasized that the treatment remains prescription-only and should be used under medical supervision.
The launches come amid rising global focus on obesity. The World Health Organization has identified obesity as a chronic disease affecting over one billion people, including around 180 million adults in India.
For investors, the development signals a major commercial opportunity for Indian pharma, as affordable access could significantly expand demand in one of the world’s largest and fastest-growing healthcare markets.